Has botulinum toxin therapy come of age: What do we know, what do we need to know, and should we use it?

Current Opinion in Urology

Volumn 19, Issue 4, 2009, Pages 347-352

  Da Silva, Carlos Martins ^a,b   Cruz, Francisco ^a,b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Benign prostatic hyperplasia; Botulinum toxin; Idiopathic detrusor overactivity; Interstitial cystitis; Neurogenic detrusor overactivity

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; PLACEBO; PURINERGIC P2X3 RECEPTOR; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; VANILLOID RECEPTOR 1;

ANTICHOLINERGIC EFFECT; ATROPHY; BLADDER ATROPHY; BLADDER CAPACITY; BLADDER CONTRACTION; CLINICAL TRIAL; CYSTALGIA; CYSTITIS; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HEMATURIA; HUMAN; INTERMITTENT CATHETERIZATION; INTERSTITIAL CYSTITIS; KIDNEY FIBROSIS; LONG TERM CARE; LOWER URINARY TRACT SYMPTOM; MUSCLE WEAKNESS; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PARALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SYNAPTOSOME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URETHROSCOPY; URINARY TRACT; URINARY TRACT INFECTION; URINE RETENTION; URODYNAMICS;

BOTULINUM TOXIN TYPE A; CYSTITIS, INTERSTITIAL; FEMALE; HUMANS; INJECTIONS; MALE; NEUROMUSCULAR AGENTS; PROSTATIC HYPERPLASIA; URINARY BLADDER, OVERACTIVE;

EID: 68249099634     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32832ae176     Document Type: Review

References (68)

1. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980; 17:21-25. (Pubitemid 10174336)
2. Ceballos-Baumann A. Botulinum toxin. Development for therapeutic purposes. Nervenarzt 2008; 79 (Suppl 1):3-8.
3. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusorsphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139:919-922. (Pubitemid 18124789)
4. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-515. (Pubitemid 38376219)
5. Schulte-Baukloh H, Schobert J, Stolze T, et al. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006; 25:110-115.
6. Cruz F, Silva C. Refractory neurogenic detrusor overactivity. Int J Clin Pract 2006; 60 (Suppl 151):22-26.
7. Del Popolo G, Filocamo MT, Li Marzi V, et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 2008; 53:1013-1119. This study demonstrates the long-term efficacy, safety and the high level of satisfaction following repeated injections of BoNT/A in NDO patients.
8. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/ neurogenic overactive bladder: a systematic literature review. Eur Urol 2008; 53:275-287. (Pubitemid 350296587)
9. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006; 176:177-185. (Pubitemid 43815416)
10. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo-controlled trial. J Urol 2007; 177:2231-2236. (Pubitemid 46726400)
11. Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62:259-264. (Pubitemid 36952073)
12. Kuo HC. Prostate botulinum A toxin injection: an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65:670-674.
13. Chuang YC, Chiang PH, Huang CC, et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005; 66:775-779.
14. Silva J, Silva C, Saraiva L, et al. Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 2008; 53:153-159.
15. Giannantoni A, Porena M, Costantini E, et al. Botulinum A toxin injection in patients with painful bladder syndrome: 1-year follow-up. J Urol 2008; 179:1031-1034.
16. Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005; 174:1873-1877. (Pubitemid 41546967)
17. Hirst GR, Watkins AJ, Guerrero K, et al. Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 2007; 69:69-73. (Pubitemid 46161676)
18. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007; 62:452-457. (Pubitemid 350308769)
19. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174:196-200. (Pubitemid 40825713)
20. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007; 41: 335-340. (Pubitemid 47357195)
21. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009; 55:100-120.
22. Del Popolo G, Li Marzi V, Lombardi G. Efficacy, safety and dosage of English botulinum toxin-A in neurogenic detrusor overactivity. Eur Urol 2004; 3 (Suppl. 3):A663.
23. Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007; 52:850-858. (Pubitemid 47126174)
24. Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47:653-659. (Pubitemid 40521915)
25. Karsenty G, Reitz A, Lindemann G, et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006; 68:1193-1197. (Pubitemid 44880353)
26. Reitz A, Denys P, Fermanian C, et al. Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007; 52:1729-1735. (Pubitemid 350064538)
27. Chenet A, Perronin-Verbe P, Le Normand L, et al. Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity. Ann Readap Med Phys 2007; 50:651-660.
28. Giannantoni A, Mearini E, Del Zingaro M, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009; 55:705-712; doi: 10.1016/j.eururo.2008.08.048. This article shows that repeated BoNT/A detrusor injections are effective and reduce the vesicoureteral reflux in NDO patients.
29. Gamé X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008; 53:613-618. This is the first article reporting a significant decrease of urinary infections in NDO patients following BoNT/A application. (Pubitemid 351178997)
30. Boy S, Seif C, Braun PM, et al. Retrospective analysis of treatment outcomes and medical care of patients with neurogenic detrusor overactivity (NDO) receiving BOTOX therapy. Eur Urol Suppl 2008; 7:212.
31. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004; 172:240-243.
32. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002; 40:599-600.
33. Kessler TM, Ryu G, Burkhard FC. Clean intermittent self-catheterization: a burden for the patient? Neurourol Urodyn 2009; 28:18-21.
34. Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004; 46:784-791. (Pubitemid 39488414)
35. Compé rat E, Reitz A, Delcourt A, et al. Histologic features in the urinary bladder wall affected from neurogenic overactivity: a comparison of iInflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006; 50:1058-1064.
36. Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008; 53:1245-1253. An important article addressing the morphological changes in the human bladder following BoNT/A application and demonstrating that BoNTA intradetrusor injections are well tolerated regarding such concerns.
37. Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinumneurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006; 49:519-527. (Pubitemid 43259563)
38. Stohrer M, Schurch B, Kramer G, et al. Botulinum A toxin in the treatment of detrusor hyperreflexia in spinal cord injury. A new alternative to medical and surgical procedures? Neurourol Urodyn 1999; 18:401-402.
39. Karsenty G, Boy S, Reitz A, et al. Botulinum toxin A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI): a prospective randomized study to compare 30 vs 10 injections sites [abstract 93]. Neururol Urodyn 2005; 24:547-548.
40. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63:868-872.
41. Rapp DE, Lucioni A, Katz EE, et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004; 63:1071-1075.
42. Karsenty G, Elzayat E, Delapparent T, et al. Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007; 177:1011-1014. (Pubitemid 46216358)
43. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312:592-596.
44. Stenmark P, Dupuy J, Imamura A, et al. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b: insight into the toxin-neuron interaction. PLoS Pathog 2008; 4:e1000129; doi:10.1371/journal.ppat.
45. Humeau Y, Doussau F, Grant NJ, et al. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000; 82:427-446. (Pubitemid 30391899)
46. Chancellor MB, Fowler CJ, Apostolidis A, et al. Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 2008; 5:319-328. An excellent review of the mechanisms of action of BoNT/A in lower urinary tract. (Pubitemid 351818884)
47. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59:1403-1406. (Pubitemid 30177357)
48. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26:785-793. (Pubitemid 41427518)
49. Rapp DE, Turk KW, Bales GT, et al. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006; 175: 1138-1142.
50. Meng J, Wang J, Lawrence G, et al. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their antinociceptive potential. J Cell Sci 2007; 120:2864-2874. (Pubitemid 47394260)
51. Lucioni A, Bales GT, Lotan TL, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008; 101:366-370.
52. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174:977-982. (Pubitemid 41140654)
53. Khera M, Somogyi GT, Kiss S, et al. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45:987-993. (Pubitemid 39164923)
54. Smith CP, Gangitano DA, Munoz A, et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 2008; 52:1068-1075.
55. Coelho A, Dinis P, Pinto R, et al. Distribution and neurochemistry of high affinity binding sites for botulinum toxin type A in the urinary tract [abstract]. Eur Urol Suppl 2009; 8:176.
56. de Paiva A, Meunier FA, Molgó J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96:3200-3205. (Pubitemid 29148868)
57. Schulte-Baukloh H, Zurawski TH, Knispel HH, et al. Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU Int 2007; 100:1075-1080. (Pubitemid 47537663)
58. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006; 175:2341-2344. (Pubitemid 43668538)
59. Liu H-T, Chancellor MB, Kuo H-C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2008. doi: 10.1016/j.eururo.2008. 04.037. [Epub ahead of print]
60. Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005; 48:984-990. (Pubitemid 41641650)
61. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180:217-222. This study brings our attention to the high percentage of urinary retention, which can occur in IDO patients after BoNT/A treatment.
62. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66:94-98.
63. Giannantoni A, Costantini E, Di Stasi SM, et al. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006; 49:704-709. (Pubitemid 43374735)
64. Pinto R, Silva A, Lopes T, et al. Intra-trigonal injection of botulinum toxin A in patients with bladder pain syndrome. Results at 9-months of follow-up [abstract]. J Urol 2009; 181:20.
65. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998; 37:44-50.
66. Silva J, Pinto R, Carvallho T, et al. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type A injection: an experimental study in the rat. Eur Urol 2008. doi:10.1016/j.eururo.2008.07.003. [Epub ahead of print] This article gives a new insight on how BoNT/A works in the prostate, suggesting that the prostate atrophy following injection of the neurotoxin may be the result of sympathetic chemodenervation of the gland.
67. Oeconomou A, Madersbacher H, Kiss G, et al. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 2008; 54:765-775. A recent and comprehensive review of the literature regarding the use of BoNT/A in the prostate.
68. Ilie CP, Chancellor MB. Perspective of Botox for treatment of male lower urinary tract symptoms. Curr Opin Urol 2009; 19:20-25. Another up-to-date article about BoNT/A effects in the prostate, reviewing the most relevant experimental and clinical data of the literature.